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Abstract 
Background and Objectives: Extensive surgery is often required for advanced soft tissue sarcoma (STS) of 
the limb. In the 1980s, a new approach was developed: isolated limb perfusion (ILP). This study aimed to assess 
incidence and impact on patient survival based on lymph node metastasis with systematic radical 
lymphadenectomy during ILP.  
Methods: Retrospective study of 57 consecutive patients treated by ILP for limb STS with simultaneous radical 
lymph node dissection in our tertiary referral center between 1992 and 2015.  
Results: Median age was 62 years (19-87) and 30 patients were male (53%). Lymph node involvement was 
observed in 13 patients (N1, 23%), regarded as metastatic spreading in 4 angiosarcomas, 3 epithelioid sarcomas, 
2 leiomyosarcomas, 2 undifferentiated sarcomas and 2 synovial sarcomas. For the N0 patient group, median 
survival was 73.9 months (CI 95% 41.9-105.9) compared to 15.1 months (CI 95% 7.4-22.6) in case of metastatic 
lymph node (p=0.002). The median disease-free survival was 33,0 months (CI 95% 12,5-53.5) in N0 group and 
8.0 months (CI 95% 4.0-11.9) in N1 (p=0.006).  
Conclusions: Lymph node metastases of STS patients selected for ILP seemed to have a negative impact on 
both overall and disease-free survival. Radical lymph node dissection should be included in ILP procedure. 
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Introduction 
Soft tissue sarcomas (STS) are tumours arising 
from connective tissues, with an incidence of about 5 
per 100’000 [1]. Their prognostic is poor, with an 
overall 50% 5-year survival [2, 3]. Previously, limb 
STS were treated by amputation until 1982 when a 
randomised controlled trial that showed no benefit 
regarding overall survival (OS) when amputation was 
compared to limb-sparing resection plus adjuvant 
radiation therapy [4]. The Isolated Limb Perfusion 
technique (ILP) was first described in 1958 [5]. The 
technique has been increasingly used since 1992, 
when a 90 % remission rate for STS treated by a 
combination of chemotherapy and Tumour Necrosis 
Factor alpha (TNFα) has been demonstrated [6]. More 
recently, a review has shown that ILP was an 
acceptable modality for neoadjuvant treatment of 
limb STS initially regarded as unresectable [7]. Three 
decades ago, former studies have retained that there 
was no indication for systematic radical lymph node 
dissection even in case of locally advanced disease 
[8-10]. Despite an increasing interest for radical lymph 
node dissection as part of treatment for sarcomas, 
there is currently no study on a standardized 
population in which radical lymph node dissection 
was performed systematically.  
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The study aim was to assess incidence and 
impact on patient survival of lymph node metastases 
in limb STS during ILP with systematic radical 
lymphadenectomy.  
Patients and Methods 
Patients 
Retrospective study including all consecutive 
patients treated by ILP for limb STS with systematic 
radical lymph node dissection in our tertiary referral 
centre between 1992 and 2015. Distant metastasis at 
diagnosis was not an exclusion criterion. Extracted 
data from medical files included demographics, 
surgical reports, radiological findings, pathological 
reports and follow-up. Some patients received 
neoadjuvant chemotherapy and/or radiotherapy 
according to local protocols, while others benefited 
from primary ILP. 
Isolated Limb Perfusion (ILP) 
The details of surgical technique have been 
widely published [6, 11-13]. In brief, the external iliac, 
the femoral or axillary artery and vein respectively of 
the diseased limbs are clamped, cannulated and 
connected to an extracorporeal circuit. In our centre, a 
radical ilio-inguinal or axillary lymph nodes 
dissection was systematically performed during 
vascular dissection to optimize vascular access. To 
minimize the risk of chemotherapy leakage, the 
collateral vessels were ligated and a tourniquet 
applied at the root of the limb. The limb was heated 
and maintained at a temperature between 38° and 40° 
Celsius. Leaks were assessed with human albumin 
radiolabelled by Tc99m and a gamma camera placed 
in precordial position [14]. Once rheological 
parameters were adjusted and stable, a single dose of 
Melphalan (Alkeran – Pro Concepta Zug AG 
Switzerland) of 13 mg/l for upper limb and 10 mg/l 
for lower limb was perfused. At the same time, from 1 
to 4 mg of recombinant Tumour Necrosis Factor alpha 
(Beromun Boehringer-Ingelheim GmbH Ingelheim 
Germany) was added [15]. After 60 minutes of 
perfusion, the limb was rinsed with up to 4 litres of 
saline solution then the systemic circulation restored.  
Radical lymph node dissection 
Pelvic radical lymph node dissections (RNLD) 
included external iliac and obturator lymph nodes. 
Axillary RLND included level I – III dissection. In this 
study, RNLD was performed regardless of clinical or 
radiological lymph node status.  
Tumour and staging 
The histologic grading system used was the 
FNCLC (Fédération National des Centres de Lutte 
contre le Cancer) [16, 17].  
Statistical analysis 
Quantitative variables were presented as mean 
(standard deviation) and compared with 
Mann–Whitney U test. Qualitative variables were 
presented as frequencies (percentage) and compared 
with Pearson’s chi-square or Fisher's exact test as 
appropriate. The OS was calculated from the date of 
ILP until patient’s death or last follow-up. The 
disease-free survival was calculated from ILP until 
local recurrence or metastases documented by MRI or 
CT-scan (regular follow-up every 3 months with 
clinical work up and imaging). Patients with initial 
distant metastases were excluded from the 
disease-free survival analysis. The survival curves 
were drawn according to Kaplan-Meier’s method 
with a Log Rank test (Mantel-Cox) to compare groups. 
A p value ≤0.05 was considered statistically 
significant. All statistical analyses were performed 
using SPSS 23.0 software (SPSS Inc., Chicago, IL). 
Ethics 
The study was conducted according to the 
Declaration of Helsinki principles of good clinical 
practice and approved by the Local Ethics’ Committee 
(Protocol number 392/11). 
Results 
Fifty-seven patients had ILP with radical lymph 
node dissection for limb STS. Four patients had a 
second ILP and only the first intervention was 
considered. Median age was 62 years (range 19-87, SD 
17.3) and 30 patients were male (53%). Seven patients 
had upper limb (12%) and 50 lower limb (88%) STS. 
Only 4 patients had synchronous distant metastases (3 
with lung and 1 with liver metastases). The various 
histological types of sarcomas are described according 
to lymph node involvement in Table 1.  
 
Table 1. Histology of sarcomas and lymph node involvement 
 N-positive  
n=13 
N-negative  
n=44 
Total 
n=57 
Angiosarcomas 4  3  7  
Epithelioid sarcomas 3  1  4  
Leiomyosarcomas 2  3  5  
Synovial sarcomas 2  2  4  
Undifferentiated sarcomas 2  8  10  
Liposarcomas 0 13  13  
Pleiomorphic sarcomas 0 5  5 
Neurofibrosarcoma 0 2  2 
Clear cell sarcoma 0 1  1  
Osteosarcoma 0 1 1  
Desmoid tumour 0 1 1  
Unclassified subtypes 0 4 4  
 
Mean number of resected lymph node was 9.5 
(range 1-41, SD 7.2). Lymph node metastatic disease 
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was observed in 13 patients (N1, 23%): 4 
angiosarcomas, 3 epithelioid sarcomas, 2 
leiomyosarcomas, 2 undifferentiated sarcomas and 2 
synovial sarcomas. No statistically significant 
correlation was found between tumour size, location 
and development of nodal metastasis (Table 2). In 
terms of tumour grades, patients with nodal 
involvement (N1) had significantly more grade 3 
compared to N0 group (69% vs. 32%, p=0.019).  
 
Table 2. Oncological properties of sarcomas and lymph node 
involvement 
 N-positive  
n=13 
N-negative  
n=44 
P-value  
Mean tumour size in cm (SD) 10.6 (5.1)  10.1 (6.1) 0.627 
Tumour grade, n (%)    
 G1 0 3 (7) 0.453 
 G2 4 (31) 27 (61) 0.052 
 G3 9 (69) 14 (32) 0.019 
Tumour localisation, n (%)    
 Upper limb   0.643 
  Proximal 1 (8) 4 (9)  
  Distal 1 (8) 2 (5)  
 Lower limb   0.161 
  Proximal 8 (61) 19 (43)  
  Distal 3 (23) 19 (43)  
 
For the N0 patient group, median survival was 
73.9 months (CI 95 % 41.9-105.9) compared to 15.1 
months (CI 95 % 7.4-22.6) in case of metastatic lymph 
node(s) (N1) (p=0.002, Fig. 1). Median disease-free 
survival was 33,0 months (CI 95% 12,5-53.5) in N0 
group and 8.0 months (CI 95% 4.0-11.9) in N1 
(p=0.006, Fig. 2). There was no significant overall or 
disease-free survival between histological types, 
although the small number of cases limited the 
analysis. 
Discussion 
This present study is one of the few that adopted 
systematic lymph node resection during ILP. Lymph 
node involvement was found in 23% of patients, 
which is slightly higher than what was usually 
published: nodal metastasis rate in the literature 
varies between 1,3 % and 24,7 % according to studied 
populations and histological subtypes [9, 10, 18-21]. 
However, a recently published retrospective study of 
patients with STS showed that nodal metastasis rates 
for STS histologic subtypes were higher than 
previously reported. This discrepancy could be 
explained by the absence of standardized lymph node 
evaluation among patients who underwent surgery 
for STS. According to other studies, RLND was 
performed only when lymph drainage area was 
included in resection’s margins [9, 21]. Moreover, 
other authors considered RLND only in patients with 
preoperative evidence of lymph nodes metastases 
[18].  
 
Figure 1. Overall Survival 
 
Figure 2. Disease-free survival 
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In the present study, lymph node metastases of 
STS seemed to have a negative impact on both OS and 
disease-free survival. There was a significant decline 
of 59-months in overall survival for patients with 
lymph node involvement. There was also a 37-month 
difference in disease-free survival. Lymph node 
involvement appeared to be a factor that clinically 
reflects the biological aggressiveness of the tumour 
[18, 21]. It is interesting to note that despite the 
negative impact of lymph node involvement, the 
American Joint Committee on Cancer (AJCC) revised 
its impact on survival. Indeed, in the two last cancer 
staging manual editions (2010 and 2016) N1 sarcomas 
were classified as stage III and no longer as stage IV 
compared to the 2002 version [22]. Stage IV now 
includes only distant metastatic patients. Lymph node 
involvement alone is not as aggravating as distant 
metastases in term of prognosis [21]. The OS benefit 
offered when the tumour did not reached the lymph 
nodes in addition together with potentially curative 
aspect of RLND are major arguments in favour of 
systematic lymph node dissection during ILP [23]. 
Moreover, the benefits of this treatment appear to be 
higher than its potential morbidities (lymphedema, 
lymphocele, infection and hematoma) [24]. The results 
from the present study suggest that lymph node 
dissection should be done systematically at least 
when an ILP procedure is performed. However, this 
cannot be claimed for sarcomas in general. 
Given the potential benefit of recognizing and 
removing occult lymph node involvement, some 
centres proposed to search sentinel node in patients 
with STS. Recently, a prospective study demonstrated 
the safety and accuracy of sentinel lymph node biopsy 
compared to PET-CT to identify therapy-changing 
nodal disease [25]. However, a meta-analysis 
recommended sentinel lymph node biopsy prior to 
radical lymphadenectomy only in sarcoma subtypes 
with a high risk of lymph node involvement [20]. A 
retrospective study of an American National Cancer 
Data Base identified that nodal metastasis rates were 
highest among patients with rhabdomyosarcoma 
(32.1%), angiosarcoma (24.1%), clear cell sarcoma 
(27.7%), and epithelioid sarcoma (31.8%), which is 
similar to this series as well as another retrospective 
study [9, 26]. From the anatomical point of view, it has 
been shown that proximal-type sarcomas have 
significantly more aggressive clinicopathological 
features, particularly lymph node metastasis [27]. 
Regarding tumour grade, high grade sarcomas tend to 
have lymph node metastases (69%), as previously 
reported by some authors in retrospective studies [26, 
28]. The fact that some STS subtypes are at high risk 
for nodal involvement should be included in 
treatment planning. For sarcomas with potentially 
high lymph node involvement risk, an active 
detection of lymph node metastases may be evaluated 
preoperatively (sentinel lymph node biopsy, MRI/CT 
or PET-CT) [29]. Unfortunately, given the small 
number of patients in the present series, conclusions 
and recommendations cannot be drawn for 
"high-risk" histologies. In the absence of clear 
recommendations, systematic lymph node dissection 
during ILP is performed in our academic center. 
However, according to results of this series and other 
retrospective studies, it could be considered to 
perform a RLND for high risk sarcomas 
(rhabdomyosarcoma, angiosarcoma, clear cell 
sarcoma, epithelioid sarcoma, synovial sarcoma) and 
not only during ILP procedures [26, 29].  
Conventional imaging modalities (CT-scan and 
MRI) show a poor sensitivity (small nodal metastases) 
and specificity (inflammation) for the detection of 
lymph node metastases. On contrary, 18F-FDG-PET 
has proven to be a promising imaging modality for 
detecting primary tumours, lymph node metastases 
and bone involvement of sarcomas, with better 
sensitivity than conventional methods including 
ultrasound and bone scintigraphy [30]. Another 
previously published study estimated a positive 
predictive value for lymph node metastasis of 27% 
[31]. In addition, 18F-FDG-PET can also be used in the 
evaluation and monitoring of tumour response to 
therapy. Nevertheless, a discrepancy in 42.9% of cases 
between the pathological evaluation and that 
obtained by PET has been described [32]. 
The main limitation of the present study is its 
retrospective nature and a relatively small number of 
patients that prevented multivariate analysis. 
Furthermore, a wide range of histological subtypes 
was included. On the other hand, sarcoma is an 
orphan disease among adult and paediatric 
populations. Currently, the lack of clear 
recommendations regarding lymphadenectomy in 
STS probably leads to an underestimation of lymph 
node metastases rate and its impact on patient’s 
mortality. Moreover, the same limit applies to 
neoadjuvant treatments, because there is currently no 
clear accepted protocol. More research is needed to 
make evidence-based recommendations in favour of 
systematic radical lymph node dissection as part of 
the surgical treatment. The definitive role of RLND in 
ILP’s for limb sarcoma patients’ needs more studies.  
In conclusion, lymph node metastases of soft 
tissue sarcoma patients selected for regional therapy 
(ILP) seemed to have a negative impact on both 
overall and disease-free survival. Systematic radical 
lymph node dissection should be included in ILP 
procedures to have more precise diagnosis with 
possible positive impact on outcome. 
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